Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Tel Hashomer Medical Research Infrastructure and Services Ltd. manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 7 pending office actions are distributed across 7 distinct examiners and 7 distinct art units. ELSHAER, ALAAELDIN M is identified as the busiest examiner, currently holding 1 busiest examiner pending action. The high number of 7 distinct art units indicates a broad technical range for the company's pending applications.
Because there are 7 distinct examiners, the company must navigate a wide variety of examiner styles and requirements. This decentralized prosecution profile suggests that no single examiner dominates the current workload. Each of the 7 pending office actions is likely being handled by a different individual, as evidenced by the 7 distinct examiners. The involvement of 7 distinct art units further emphasizes the diversity of the technology being patented. ELSHAER, ALAAELDIN M is the busiest examiner but only handles 1 busiest examiner pending action, showing an even distribution of work. This complexity requires a robust management strategy to ensure consistency across many different points of contact at the USPTO.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (14%) |
| §101 + other | 1 (14%) |
| §103 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELSHAER, ALAAELDIN M | 1 | 36.1% | +30.5% |
| VILLECCO, JOHN M | 1 | 64.5% | +9.5% |
| BECKHARDT, LYNDSEY MARIE | 1 | 27.8% | +48.0% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| FREDRICKSON, COURTNEY B | 1 | 75.6% | +29.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270852 | AURICULAR RECONSTRUCTION USING 3D PRINTED AUTOLOGOUS CARTILAGE TISSUE | BECKHARDT, LYNDSEY MARIE | 28d overdue |
| 18256747 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | ROZOF, TIMOTHY R | 5d |
| 18280254 | MACHINE LEARNING MODELS FOR PREDICTION OF UNPLANNED CESAREAN DELIVERY | ELSHAER, ALAAELDIN M | 14d |
| 18223106 | METHOD AND SYSTEM FOR IMAGING EYE BLOOD VESSELS | VILLECCO, JOHN M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270852 | AURICULAR RECONSTRUCTION USING 3D PRINTED AUTOLOGOUS CARTILAGE TISSUE | BECKHARDT, LYNDSEY MARIE | 28d overdue |
| 18256747 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | ROZOF, TIMOTHY R | 5d |
| 18280254 | MACHINE LEARNING MODELS FOR PREDICTION OF UNPLANNED CESAREAN DELIVERY | ELSHAER, ALAAELDIN M | 14d |
| 17391227 | METHOD FOR DELIVERY OF COMPOSITIONS TO THE EYE | FREDRICKSON, COURTNEY B | 39d |
| 17430072 | DIAGNOSIS AND TREATMENT OF MEDULLOBLASTOMA | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 3687 | 1 |
| 2671 | 1 |
| 1613 | 1 |
| 1625 | 1 |
| 1658 | 1 |
| 1637 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280254 | MACHINE LEARNING MODELS FOR PREDICTION OF UNPLANNED CESAREAN DELIVERY | ELSHAER, ALAAELDIN M | 3687 | §101 | Non-Final OA | 14d | Pending | Sep 04, 2023 |
| 18223106 | METHOD AND SYSTEM FOR IMAGING EYE BLOOD VESSELS | VILLECCO, JOHN M | 2671 | §102§103 | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18270852 | AURICULAR RECONSTRUCTION USING 3D PRINTED AUTOLOGOUS CARTILAGE TISSUE | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112 | Final Rejection | 28d overdue | Pending | Jul 04, 2023 |
| 18256747 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | ROZOF, TIMOTHY R | 1625 | §101§102 | Final Rejection | 5d | Pending | Jun 09, 2023 |
| 17989817 | TARGETING G3BP AGGREGATION TO PREVENT NEURODEGENERATION | STEELE, AMBER D | 1658 | §102§103§112DP | Final Rejection | 51d overdue | Pending | Nov 18, 2022 |
| 17430072 | DIAGNOSIS AND TREATMENT OF MEDULLOBLASTOMA | PERSONS, JENNA L | 1637 | §103 | Final Rejection | — | Pending | Aug 11, 2021 |
| 17391227 | METHOD FOR DELIVERY OF COMPOSITIONS TO THE EYE | FREDRICKSON, COURTNEY B | 3783 | §112 | Non-Final OA | 39d | Pending | Aug 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial